Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-769-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.17 million
Profitability
Miscellaneous
Employees80
Next Earnings Date2/20/2020 (Estimated)
OptionableNot Optionable
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) announced its quarterly earnings results on Thursday, August, 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.16. Pro-Dex had a net margin of 13.67% and a return on equity of 22.71%. View Pro-Dex's Earnings History.
When is Pro-Dex's next earnings date?
What price target have analysts set for PDEX?
1 brokers have issued twelve-month target prices for Pro-Dex's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Pro-Dex's stock price to reach $20.00 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Pro-Dex.
What is the consensus analysts' recommendation for Pro-Dex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pro-Dex.
Has Pro-Dex been receiving favorable news coverage?
Media headlines about PDEX stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pro-Dex earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Pro-Dex.
Are investors shorting Pro-Dex?
Pro-Dex saw a increase in short interest in January. As of January 31st, there was short interest totalling 14,600 shares, an increase of 49.0% from the January 15th total of 9,800 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is currently 0.9 days. Currently, 0.5% of the company's stock are sold short. View Pro-Dex's Current Options Chain.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Apyx Medical (APYX), Westaim (WEDXF), GenMark Diagnostics (GNMK), Repro Med Systems (KRMD), Repro-Med Systems (REPR), iCAD (ICAD), Venus Concept (VERO), Vapotherm (VAPO), Soliton (SOLY), RenovaCare (RCAR), TELA Bio (TELA), Pulse Biosciences (PLSE), Cytosorbents (CTSO), Liquidia Technologies (LQDA) and BRAINSWAY LTD/S (BWAY).
What other stocks do shareholders of Pro-Dex own?
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
Who are Pro-Dex's major shareholders?
Pro-Dex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.39%), THB Asset Management (2.29%), LSV Asset Management (1.27%), Punch & Associates Investment Management Inc. (0.84%), Alambic Investment Management L.P. (0.47%) and Wedge Capital Management L L P NC (0.29%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson and Raymond E Cabillot. View Institutional Ownership Trends for Pro-Dex.
Which institutional investors are selling Pro-Dex stock?
PDEX stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P. and Wedge Capital Management L L P NC. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, David Hovda and Raymond E Cabillot. View Insider Buying and Selling for Pro-Dex.
Which institutional investors are buying Pro-Dex stock?
PDEX stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, LSV Asset Management, THB Asset Management and Punch & Associates Investment Management Inc.. View Insider Buying and Selling for Pro-Dex.
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $18.73.
How big of a company is Pro-Dex?
What is Pro-Dex's official website?
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
